Effects of Varenicline on Lung Tissue in the Animal Model

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2020 Mar 5

PMID 32130342

Citations 1

Authors

Hilal Ermis

Hakan Parlakpinar

Hulya Elbe

Nigar Vardi

Alaaddin Polat

Gazi Gulbas

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate acute and chronic effects of varenicline on lung tissue in an experimental study.

Methods: A total of 34 rats were randomly allocated into study (varenicline) and control groups. The rats were divided into two groups (i) control group, (ii) varenicline group. Then, the rats in the each group were sub-divided equally in turn as acute (C1; V1) and chronic (C2; V2) ; all rats of acute and chronic groups were sacrificed under the anesthesia on the 45th day for acute group [C1 (n=5) and V1 (n=12)] and the 90th day for chronic group [C2 (n=5) and V2 (n=12)], respectively. Thus, biochemical and histopathological analysis were carried out.

Results: Thirty four rats completed the study, 24 were in varenicline group and 10 were in control group. In chronic exposure to varenicline, oxidant levels comprising of malondialdehyde (MDA), and myeloperoxidase (MPO) increased and superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GPx) levels, named as antioxidants, decreased significantly when compared to the control group. MDA and MPO levels were also significantly higher and SOD, CAT, GPx, GSH levels were also significantly lower in chronic varenicline group when compared to acute varenicline group. These findings were also supported by histopathological observations.

Conclusion: This is the first study, which evaluated pulmonary effects of varenicline experimentally on an animal model. It was observed that chronic varenicline treatments cause inflammation and lung cell injury.

Citing Articles

Effects of smoking cessation using varenicline on the serum concentrations of oxidized high-density lipoprotein: Comparison with high-density lipoprotein cholesterol.

Umeda A, Miyagawa K, Mochida A, Takeda H, Ohira Y, Kato T PLoS One. 2022; 17(11):e0277766.

PMID: 36449474 PMC: 9710765. DOI: 10.1371/journal.pone.0277766.

References

Tashkin D, Rennard S, Hays J, Ma W, Lawrence D, Lee T . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2010; 139(3):591-599. DOI: 10.1378/chest.10-0865. View

Sansores R, Ramirez-Venegas A, Arellano-Rocha R, Noe-Diaz V, Garcia-Gomez L, Perez Bautista O . Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study. Ther Adv Respir Dis. 2016; 10(5):383-90. PMC: 5933615. DOI: 10.1177/1753465816654823. View

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

Rollema H, Coe J, Chambers L, Hurst R, Stahl S, Williams K . Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007; 28(7):316-25. DOI: 10.1016/j.tips.2007.05.003. View

Hays J, Ebbert J . Varenicline for tobacco dependence. N Engl J Med. 2008; 359(19):2018-24. PMC: 2959114. DOI: 10.1056/NEJMct0800146. View

Schiller H, Reilly P, Bulkley G . Tissue perfusion in critical illnesses. Antioxidant therapy. Crit Care Med. 1993; 21(2 Suppl):S92-102. View

Sharma V, McNeill J . To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol. 2009; 157(6):907-21. PMC: 2737649. DOI: 10.1111/j.1476-5381.2009.00267.x. View

Hunninghake G, Gallin J, Fauci A . Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis. 1978; 117(1):15-23. DOI: 10.1164/arrd.1978.117.1.15. View

Fernandez E, Schiaffino A, Borrell C, Benach J, Ariza C, Ramon J . Social class, education, and smoking cessation: Long-term follow-up of patients treated at a smoking cessation unit. Nicotine Tob Res. 2006; 8(1):29-36. DOI: 10.1080/14622200500264432. View

10.

Sterling L, Windle S, Filion K, Touma L, Eisenberg M . Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2016; 5(2). PMC: 4802486. DOI: 10.1161/JAHA.115.002849. View

11.

McClure E, Baker N, Gipson C, Carpenter M, Roper A, Froeliger B . An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse. 2014; 41(1):52-6. PMC: 4262740. DOI: 10.3109/00952990.2014.933839. View

12.

Watkins S, Koob G, Markou A . Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000; 2(1):19-37. DOI: 10.1080/14622200050011277. View

13.

Zaccarelli-Magalhaes J, Moreira N, Sandini T, de Abreu G, Sanchez-Sarmiento A, Ricci E . Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Haematological, Biochemical and Anatomopathological Studies. Basic Clin Pharmacol Toxicol. 2017; 122(3):305-309. DOI: 10.1111/bcpt.12913. View

14.

Domagala-Kulawik J . Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol. 2009; 59 Suppl 6:19-34. View

15.

Lewis D, Williams T, Beck S . Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development. J Appl Toxicol. 2014; 34(4):319-31. DOI: 10.1002/jat.2950. View

16.

Mihalak K, Carroll F, Luetje C . Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006; 70(3):801-5. DOI: 10.1124/mol.106.025130. View

17.

Sun Y, Oberley L, Li Y . A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988; 34(3):497-500. View

18.

Paglia D, Valentine W . Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967; 70(1):158-69. View

19.

Cahill K, Stevens S, Perera R, Lancaster T . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; (5):CD009329. PMC: 8406789. DOI: 10.1002/14651858.CD009329.pub2. View

20.

Gratziou C . Respiratory, cardiovascular and other physiological consequences of smoking cessation. Curr Med Res Opin. 2009; 25(2):535-45. DOI: 10.1185/03007990802707642. View